Emerging and potential treatment options for sarcoidosis

References

• Judson MA. Clinical features of sarcoidosis: a comprehensive review. Clinic Rev Allerg Immunol. 2015;49(1):63–75.
   PubMed Web of Science ®Google Scholar
• Gibson GJ, Prescott RJ, Muers MF, et al. British thoracic society sarcoidosis study: effects of long term corticosteroid treatment. Thorax. 1996;51(3):238–247.
   PubMed Web of Science ®Google Scholar
• Selroos O, Sellergren TL. Corticosteroid therapy of pulmonary sarcoidosis. A prospective evaluation of alternate day and daily dosage in stage II disease. Scand J Respir Dis. 1979;60(4):215–221.
   PubMedGoogle Scholar
• Israel HL, Fouts DW, Beggs RA. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis. 1973;107(4):609–614.
   PubMed Web of Science ®Google Scholar
• James DG, Carstairs LS, Trowell J, et al. Treatment of sarcoidosis. Report of a controlled therapeutic trial. Lancet. 1967;2(7515):526–528.
   PubMed Web of Science ®Google Scholar
• Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med. 1994;149:893–898.
   PubMed Web of Science ®Google Scholar
• Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest. 1997;111(3):623–631.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Nagai S, Balter M, et al. Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG task force. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(1):56–64.
   PubMed Web of Science ®Google Scholar
• Zissel G, Müller-Quernheim J. Cellular players in the immunopathogenesis of sarcoidosis. Clin Chest Med. 2015;36(4):549–560.
   PubMed Web of Science ®Google Scholar
• Loke WS, Herbert C, Thomas PS. Sarcoidosis: immunopathogenesis and immunological markers. Int J Chronic Dis. 2013;2013:928601.
   PubMedGoogle Scholar
• Beegle SH, Barba K, Gobunsuy R, et al. Current and emerging pharmacological treatments for sarcoidosis: a review. Drug Des Devel Ther. 2013;7:325–338.
   PubMed Web of Science ®Google Scholar
• Chen ES. Innate immunity in sarcoidosis pathobiology. Curr Opin Pulm Med. 2016;22(5):469–475.
   PubMed Web of Science ®Google Scholar
• Chen ES, Song Z, Willett MH, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med. 2010;181(4):360–373.
   PubMed Web of Science ®Google Scholar
• Judson MA. The treatment of pulmonary sarcoidosis. Respir Med. 2012;106(10):1351–1361.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17(1):60–66.
   PubMed Web of Science ®Google Scholar
• Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med. 2010;104(5):717–723.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21(1):43–48.
   PubMed Web of Science ®Google Scholar
• Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J. 2011;38(5):1145–1150.
   PubMed Web of Science ®Google Scholar
• Müller-Quernheim J, Kienast K, Held M, et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999;14(5):1117–1122.
   PubMed Web of Science ®Google Scholar
• Androdias G, Maillet D, Marignier R, et al. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology. 2011;76(13):1168–1172.
   PubMed Web of Science ®Google Scholar
• Moudgil A, Przygodzki RM, Kher KK. Successful steroid-sparing treatment of renal sarcoidosis with mycophenolate mofetil. Pediatr Nephrol. 2006;21(2):281–285.
   PubMed Web of Science ®Google Scholar
• Vorselaars ADM, Wuyts WA, Vorselaars VMM, et al. Methotrexate vs. azathioprine in second-line therapy of sarcoidosis. Chest. 2013;144(3):805–812.
   PubMed Web of Science ®Google Scholar
• Baltzan M, Mehta S, Kirkham TH, et al. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med. 1999;160(1):192–197.
   PubMed Web of Science ®Google Scholar
• Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol. 1990;23(3 Pt 1):487–489.
   PubMed Web of Science ®Google Scholar
• Adams JS, Diz MM, Sharma OP. Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy. Ann Intern Med. 1989;111(5):437–438.
   PubMed Web of Science ®Google Scholar
• Callejas-Rubio JL, López-Pérez L, Ortego-Centeno N. Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis. Ther Clin Risk Manag. 2008;4(6):1305–1313.
   PubMedGoogle Scholar
• Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795–802.
   PubMed Web of Science ®Google Scholar
• Rossman MD, Newman LS, Baughman RP, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23(3):201–208.
   PubMed Web of Science ®Google Scholar
• Sweiss NJ, Welsch MJ, Curran JJ, et al. Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum. 2005;53(5):788–791.
   PubMedGoogle Scholar
• Santos E, Shaunak S, Renowden S, et al. Treatment of refractory neurosarcoidosis with Infliximab. J Neurol Neurosurg Psychiatry. 2010;81(3):241–246.
   PubMed Web of Science ®Google Scholar
• Sodhi M, Pearson K, White ES, et al. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med. 2009;103(2):268–273.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, Ingledue R, et al. Management of ocular sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(1):26–33.
   PubMed Web of Science ®Google Scholar
• Uthman I, Touma Z, Khoury M. Cardiac sarcoidosis responding to monotherapy with infliximab. Clin Rheumatol. 2007;26(11):2001–2003.
   PubMed Web of Science ®Google Scholar
• Barnabe C, McMeekin J, Howarth A, et al. Successful treatment of cardiac sarcoidosis with infliximab. J Rheumatol. 2008;35(8):1686–1687.
   PubMed Web of Science ®Google Scholar
• Seitzer U, Swider C, Stüber F, et al. Tumour necrosis factor alpha promoter gene polymorphism in sarcoidosis. Cytokine. 1997;9(10):787–790.
   PubMed Web of Science ®Google Scholar
• Wijnen PA, Nelemans PJ, Verschakelen JA, et al. The role of tumor necrosis factor alpha G-308A polymorphisms in the course of pulmonary sarcoidosis. Tissue Antigens. 2010;75(3):262–268.
   PubMedGoogle Scholar
• Wijnen PA, Cremers JP, Nelemans PJ, et al. Association of the TNF-α G-308A polymorphism with TNF-inhibitor response in sarcoidosis. Eur Respir J. 2014;43(6):1730–1739.
   PubMed Web of Science ®Google Scholar
• Sweiss NJ, Barnathan ES, Lo K, et al. C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27(1):49–56.
   PubMed Web of Science ®Google Scholar
• Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31(4):299–316.
   PubMed Web of Science ®Google Scholar
• Sweiss NJ, Noth I, Mirsaeidi M, et al. Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(1):46–54.
   PubMed Web of Science ®Google Scholar
• Judson MA. Advances in the diagnosis and treatment of sarcoidosis. F1000Prime Rep. 2014;6:89.
   PubMedGoogle Scholar
• Erckens RJ, Mostard RL, Wijnen PA, et al. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012;250(5):713–720.
   PubMed Web of Science ®Google Scholar
• Pariser RJ, Paul J, Hirano S, et al. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013;68(5):765–773.
   PubMed Web of Science ®Google Scholar
• Milman N, Graudal N, Loft A, et al. Effect of the TNF-α inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J. 2012;6(4):238–247.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25(2):76–89.
   PubMed Web of Science ®Google Scholar
• Judson MA, Baughman RP, Costabel U, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014;44(5):1296–1307.
   PubMed Web of Science ®Google Scholar
• Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003;124(1):177–185.
   PubMed Web of Science ®Google Scholar
• Sweiss NJ, Baughman RP. Tumor necrosis factor inhibition in the treatment of refractory sarcoidosis: slaying the dragon? J Rheumatol. 2007;34(11):2129–2131.
   PubMed Web of Science ®Google Scholar
• Decock A, Van Assche G, Vermeire S, et al. Sarcoidosis-like lesions: another paradoxical reaction to anti-TNF therapy? J Crohns Colitis. 2017;11(3):378–383.
   PubMed Web of Science ®Google Scholar
• Marcella S, Welsh B, Foley P. Development of sarcoidosis during adalimumab therapy for chronic plaque psoriasis. Australas J Dermatol. 2011;52(3):e8–11.
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098–1104.
   PubMed Web of Science ®Google Scholar
• Gómez-Reino JJ, Carmona L, Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007;57(5):756–761.
   PubMed Web of Science ®Google Scholar
• Fausel R, Afzali A. Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists. Ther Clin Risk Manag. 2015;11:63–73.
   PubMed Web of Science ®Google Scholar
• Caspersen S, Elkjaer M, Riis L, et al. Danish Crohn colitis database. Infliximab for inflammatory bowel disease in treatment of life threatening haemoptysis Denmark 1999–2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol. 2008;6(11):1212–1217.
   PubMed Web of Science ®Google Scholar
• Wong AK, Kerkoutian S, Said J, et al. Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta- analysis of published randomized controlled studies. Clin Rheumatol. 2012;31(4):631–636.
   PubMed Web of Science ®Google Scholar
• Stagaki E, Mountford WK, Lackland DT, et al. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest. 2009;135(2):468–476.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Judson MA, Ingledue R, et al. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol. 2012;148(2):262–264.
   PubMedGoogle Scholar
• Park MK, Fontana JR, Babaali H, et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26(2):121–131.
   PubMed Web of Science ®Google Scholar
• Zabel P, Entzian P, Dalhoff K, et al. In treatment of sarcoidosis. Am J Respir Crit Care Med. 1997;155(5):1665–1669.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Birring S, Judson MA, et al. A double blind, placebo controlled study of roflumilast to prevent acute events in fibrotic sarcoidosis. Am J Respir Crit Care Med. 2017;195:A4752.
   Web of Science ®Google Scholar
• Sweiss NJ, Lower EE, Mirsaeidi M, et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J. 2014;43(5):1525–1528.
   PubMed Web of Science ®Google Scholar
• Cinetto F, Compagno N, Scarpa R, et al. Rituximab in refractory sarcoidosis: a single centre experience. Clin Mol Allergy. 2015;13(1):19.
   PubMedGoogle Scholar
• Belkhou A, Younsi R, El Bouchti I, et al. Rituximab as a treatment alternative in sarcoidosis. Joint Bone Spine. 2008;75(4):511–512.
   PubMed Web of Science ®Google Scholar
• Bomprezzi R, Pati S, Chansakul C, et al. A case of neurosarcoidosis successfully treated with rituximab. Neurology. 2010;75(6):568–570.
   PubMed Web of Science ®Google Scholar
• Bachelez H, Senet P, Cadranel J, et al. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol. 2001;137(1):69–73.
   PubMedGoogle Scholar
• Baughman RP, Judson MA, Teirstein AS, et al. Thalidomide for chronic sarcoidosis. Chest. 2002;122(1):227–232.
   PubMed Web of Science ®Google Scholar
• Droitcourt C, Rybojad M, Porcher R, et al. A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis. Chest. 2014;146(4):1046–1054.
   PubMed Web of Science ®Google Scholar
• Fazzi P, Manni E, Cristofani R, et al. Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids. Biomed Pharmacother. 2012;66(4):300–307.
   PubMed Web of Science ®Google Scholar
• York EL, Kovithavongs T, Man SF, et al. Cyclosporine and chronic sarcoidosis. Chest. 1990;98(4):1026–1029.
   PubMed Web of Science ®Google Scholar
• Stern BJ, Schonfeld SA, Sewell C, et al. The treatment of neurosarcoidosis with cyclosporine. Arch Neurol. 1992;49(10):1065–1072.
   PubMedGoogle Scholar
• Miller MA, Bass HE. Effect of Acthar-c (ACTH) in sarcoidosis. Ann Intern Med. 1952;37(4):776–784.
   PubMed Web of Science ®Google Scholar
• Chapelon-Abric C, De Zuttere D, Duhaut P, et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore). 2004;83(6):315–334.
   PubMed Web of Science ®Google Scholar
• Doty JD, Mazur JE, Judson MA. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest. 2003;124(5):2023–2026.
   PubMed Web of Science ®Google Scholar
• Goldszer RC, Galvanek EG, Lazarus JM. Glomerulonephritis in a patient with sarcoidosis. Report of a case and review of the literature. Arch Pathol Lab Med. 1981;105(9):478–481.
   PubMed Web of Science ®Google Scholar
• Rosen Y, Moon S, Huang CT, et al. Granulomatous pulmonary angiitis in sarcoidosis. Arch Pathol Lab Med. 1977;101(4):170–174.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Sweiss N, Keijsers R, et al. Repository corticotropin for chronic pulmonary sarcoidosis. Lung. 2017;195(3):313–322.
   PubMed Web of Science ®Google Scholar
• Marques LJ, Zheng L, Poulakis N, et al. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med. 1999;159(2):508–511.
   PubMed Web of Science ®Google Scholar
• Kataria YP, Holter JF. Immunology of sarcoidosis. Clin Chest Med. 1997;18(4):719–739.
   PubMed Web of Science ®Google Scholar
• Negi M, Takemura T, Guzman J, et al. Localization of propionibacterium acnes in granulomas supports a possible etiologic link between sarcoidosis and the bacterium. Mod Pathol. 2012;25(9):1284–1297.
   PubMed Web of Science ®Google Scholar
• Yamada T, Eishi Y, Ikeda S, et al. In situ localization of propionibacterium acnes DNA in lymph nodes from sarcoidosis patients by signal amplification with catalysed reporter deposition. J Pathol. 2002;198(4):541–547.
   PubMed Web of Science ®Google Scholar
• Thong YH, Ferrante A. Effect of tetracycline treatment on immunological responses in mice. Clin Exp Immunol. 1980;39(3):728–732.
   PubMed Web of Science ®Google Scholar
• Webster G, FToso SM, Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C. Arch Dermatol. 1994;130(6):748–752.
   Google Scholar
• Ye Q, Chen B, Tong Z, et al. Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease. Eur Respir J. 2006;28(4):824–831.
   PubMed Web of Science ®Google Scholar
• Demeter SL. Myocardial sarcoidosis unresponsive to steroids. Treatment with cyclophosphamide. Chest. 1988;94(1):202–203.
   PubMed Web of Science ®Google Scholar
• Takemura T, Matsui Y, Oritsu M, et al. Pulmonary vascular involvement in sarcoidosis: granulomatous angiitis and microangiopathy in transbronchial lung biopsies. Virchows Archiv. 1991;418(4):361–368.
   Web of Science ®Google Scholar
• Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J. 2009;157(1):9–21.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Engel PJ, Taylor L, et al. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest. 2010;138(5):1078–1085.
   PubMed Web of Science ®Google Scholar
• Swigris JJ, Olson AL, Huie TJ, et al. Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007. Chest. 2011;140(5):1261–1266.
   PubMed Web of Science ®Google Scholar
• Westcott JL, DeGraff AC Jr. Sarcoidosis, hilar adenopathy, and pulmonary artery narrowing. Radiology. 1973;108(3):585–586.
   PubMed Web of Science ®Google Scholar
• Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax. 2006;61(1):68–74.
   PubMed Web of Science ®Google Scholar
• Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest. 2006;129(5):1246–1252.
   PubMed Web of Science ®Google Scholar
• Shorr AF, Helman DL, Davies DB, et al. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J. 2005;25(5):783–788.
   PubMed Web of Science ®Google Scholar
• Milman N, Burton CM, Iversen M, et al. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J Heart Lung Transplant. 2008;27(3):329–334.
   PubMed Web of Science ®Google Scholar
• Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest. 2003;124(3):922–928.
   PubMed Web of Science ®Google Scholar
• Arcasoy SM, Christie JD, Pochettino A, et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest. 2001;120(3):873–880.
   PubMed Web of Science ®Google Scholar
• Judson MA, Highland KB, Kwon S, et al. Ambrisentan for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(2):139–145.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Engel PJ, Meyer CA, et al. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23(2):108–116.
   PubMed Web of Science ®Google Scholar
• Keir GJ, Walsh SL, Gatzoulis MA, et al. Treatment of sarcoidosis-associated pulmonary hypertension: a single centre retrospective experience using targeted therapies. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):82–90.
   PubMed Web of Science ®Google Scholar
• Barnett CF, Bonura EJ, Nathan SD, et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest. 2009;135(6):1455–1461.
   PubMed Web of Science ®Google Scholar
• Fisher KA, Serlin DM, Wilson KC, et al. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest. 2006;130(5):1481–1488.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Judson MA, Lower EE, et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26(2):110–120.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Culver DA, Cordova FC, et al. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest. 2014;145(4):810–817.
   PubMed Web of Science ®Google Scholar
• Dobarro D, Schreiber BE, Handler C, et al. Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data. Am J Cardiol. 2013;111(2):278–285.
   PubMed Web of Science ®Google Scholar
• Judson MA, Baughman RP. Worsening of pulmonary sarcoidosis. Curr Opin Pulm Med. 2014;20(5):508–516.
   PubMed Web of Science ®Google Scholar
• Lewis MM, Mortelliti MP, Yeager H, et al. Clinical bronchiectasis complicating pulmonary sarcoidosis: case series of seven patients. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19(2):154–159.
   PubMed Web of Science ®Google Scholar
• Nardi A, Brillet PY, Letoumelin P, et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J. 2011;38(6):1368–1373.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients. Respir Med. 2013;107(12):2009–2013.
   PubMed Web of Science ®Google Scholar
• Judson MA, Stevens DA. The treatment of pulmonary aspergilloma. Curr Opin Investig Drugs. 2001;2(10):1375–1377.
   PubMedGoogle Scholar
• Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis complicating sarcoidosis. Eur Respir J. 2013;41(3):621–626.
   PubMed Web of Science ®Google Scholar
• Aspergilloma and residual tuberculous cavities–the results of a resurvey: A report from the Research Committee of the British Thoracic and Tuberculosis Association. Tubercle. 1970;51(3):227–245.
   PubMedGoogle Scholar
• Kravitz JN, Berry MW, Schabel SI, et al. A modern series of percutaneous intracavitary instillation of amphotericin B for the treatment of severe hemoptysis from pulmonary aspergilloma. Chest. 2013;143(5):1414–1421.
   PubMed Web of Science ®Google Scholar
• Tomlinson JR, Sahn SA. Aspergilloma in sarcoid and tuberculosis. Chest. 1987;92(3):505–508.
   PubMedGoogle Scholar
• Pena TA, Soubani AO, Samavati L. Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature. Lung. 2011;189(2):167–172.
   PubMed Web of Science ®Google Scholar
• Khan MA, Dar AM, Kawoosa NU, et al. Clinical profile and surgical outcome for pulmonary aspergilloma: nine year retrospective observational study in a tertiary care hospital. Int J Surg. 2011;9(3):267–271.
   PubMed Web of Science ®Google Scholar
• Israel HL, Lenchner GS, Atkinson GW. Sarcoidosis and aspergilloma. The role of surgery. Chest. 1982;82(4):430–432.
   PubMed Web of Science ®Google Scholar
• Riscili BP, Wood KL. Noninvasive pulmonary Aspergillus infections. Clin Chest Med. 2009;30(2):315–335, vii.
   PubMed Web of Science ®Google Scholar
• Regnard JF, Icard P, Nicolosi M, et al. Aspergilloma: a series of 89 surgical cases. Ann Thorac Surg. 2000;69(3):898–903.
   PubMed Web of Science ®Google Scholar
• Kaestel M, Meyer W, Mittelmeier HO, et al. Pulmonary aspergilloma - clinical findings and surgical treatment. Thorac Cardiovasc Surg. 1999;47(5):340–345.
   PubMed Web of Science ®Google Scholar
• Mossi F, Maroldi R, Battaglia G, et al. Indicators predictive of success of embolisation: analysis of 88 patients with haemoptysis. Radiol Med. 2003;105(1–2):48–55.
   PubMedGoogle Scholar
• Shin BS, Jeon GS, Lee SA, et al. Bronchial artery embolisation for the management of haemoptysis in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2011;15(8):1093–1098.
   PubMed Web of Science ®Google Scholar
• Chun JY, Belli AM. Immediate and long-term outcomes of bronchial and non-bronchial systemic artery embolisation for the management of haemoptysis. Eur Radiol. 2010;20(3):558–565.
   PubMed Web of Science ®Google Scholar
• Uflacker R, Kaemmerer A, Neves C, et al. Management of massive hemoptysis by bronchial artery embolization. Radiology. 1983;146(3):627–634.
   PubMed Web of Science ®Google Scholar
• Remy J, Arnaud A, Fardou H, et al. Treatment of hemoptysis by embolization of bronchial arteries. Radiology. 1977;122(1):33–37.
   PubMed Web of Science ®Google Scholar
• Hargis JL, Bone RC, Stewart J, et al. Intracavitary amphotereicin B in the treatment of symptomatic pulmonary aspergillomas. Am J Med. 1980;68(3):389–394.
   PubMed Web of Science ®Google Scholar
• Hammerman KJ, Sarosi GA, Tosh FE. Amphotericin B in the treatment of saprophytic forms of pulmonary aspergillosis. Am Rev Respir Dis. 1974;109(1):57–62.
   PubMedGoogle Scholar
• Tsubura E. [Multicenter clinical trial of itraconazole in the treatment of pulmonary aspergilloma. Pulmonary Aspergilloma Study Group]. Kekkaku. 1997;72(10):557–564.
   PubMedGoogle Scholar
• Fujita M, Tao Y, Kajiki A, et al. The clinical efficacy and safety of micafungin-itraconazole combination therapy in patients with pulmonary aspergilloma. J Infect Chemother. 2012;18(5):668–674.
   PubMed Web of Science ®Google Scholar
• Campbell JH, Winter JH, Richardson MD, et al. Treatment of pulmonary aspergilloma with itraconazole. Thorax. 1991;46(11):839–841.
   PubMed Web of Science ®Google Scholar
• De Beule K, De Doncker P, Cauwenbergh G, et al. The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982–1987). Mycoses. 1988;31(9):476–485.
   PubMed Web of Science ®Google Scholar
• Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol. 1990;23(3 Pt 2):607–614.
   PubMed Web of Science ®Google Scholar
• Lee KS, Kim HT, Kim YH, et al. Treatment of hemoptysis in patients with cavitary aspergilloma of the lung: value of percutaneous instillation of amphotericin B. Ajr. 1993;161(4):727–731.
   PubMed Web of Science ®Google Scholar
• Shapiro MJ, Albelda SM, Mayock RL, et al. Severe hemoptysis associated with pulmonary aspergilloma. Percutaneous intracavitary treatment. Chest. 1988;94(6):1225–1231.
   PubMed Web of Science ®Google Scholar
• Rumbak M, Kohler G, Eastrige C, et al. Topical treatment of life threatening haemoptysis from aspergillomas. Thorax. 1996;51(3):253–255.
   PubMed Web of Science ®Google Scholar
• Munk PL, Vellet AD, Rankin RN, et al. Intracavitary aspergilloma: transthoracic percutaneous injection of amphotericin gelatin solution. Radiology. 1993;188(3):821–823.
   PubMed Web of Science ®Google Scholar
• Giron J, Poey C, Fajadet P, et al. CT-guided percutaneous treatment of inoperable pulmonary aspergillomas: a study of 40 cases. Eur J Radiol. 1998;28(3):235–242.
   PubMed Web of Science ®Google Scholar
• Jackson M, Flower CD, Shneerson JM. Treatment of symptomatic pulmonary aspergillomas with intracavitary instillation of amphotericin B through an indwelling catheter. Thorax. 1993;48(9):928–930.
   PubMed Web of Science ®Google Scholar
• Kravitz JN, Steed LL, Judson MA. Intracavitary voriconazole for the treatment of hemoptysis complicating Pseudallescheria angusta pulmonary mycetomas in fibrocystic sarcoidosis. Med Mycol. 2011;49(2):198–201.
   PubMed Web of Science ®Google Scholar
• Hoitsma E, Marziniak M, Faber CG, et al. Small fibre neuropathy in sarcoidosis. Lancet. 2002;359(9323):2085–2086.
   PubMed Web of Science ®Google Scholar
• Bakkers M, Merkies IS, Lauria G, et al. Intraepidermal nerve fiber density and its application in sarcoidosis. Neurology. 2009;73(14):1142–1148.
   PubMed Web of Science ®Google Scholar
• Tavee J, Culver D. Sarcoidosis and small-fiber neuropathy. Curr Pain Headache Rep. 2011;15(3):201–206.
   PubMed Web of Science ®Google Scholar
• Parambil JG, Tavee JO, Zhou L, et al. Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis. Respir Med. 2011;105(1):101–105.
   PubMed Web of Science ®Google Scholar
• Atherton DD, Facer P, Roberts KM, et al. Use of the novel Contact Heat Evoked Potential Stimulator (CHEPS) for the assessment of small fibre neuropathy: correlations with skin flare responses and intra-epidermal nerve fibre counts. BMC Neurology. 2007;7:21.
   PubMed Web of Science ®Google Scholar
• Truini A, Galeotti F, Romaniello A, et al. Laser-evoked potentials: normative values. Clin Neurophysiol. 2005;116(4):821–826.
   PubMed Web of Science ®Google Scholar
• Low PA, Caskey PE, Tuck RR, et al. Quantitative sudomotor axon reflex test in normal and neuropathic subjects. Ann Neurol. 1983;14(5):573–580.
   PubMed Web of Science ®Google Scholar
• Reulen JP, Lansbergen MD, Verstraete E, et al. Comparison of thermal threshold tests to assess small nerve fiber function: limits vs. levels. Clin Neurophysiol. 2003;114(3):556–563.
   PubMed Web of Science ®Google Scholar
• Mainka T, Maier C, Enax-Krumova EK. Neuropathic pain assessment: update on laboratory diagnostic tools. Curr Opin Anaesthesiol. 2015;28(5):537–545.
   PubMed Web of Science ®Google Scholar
• Lauria G, Cornblath DR, Johansson O, et al. EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol. 2005;12(10):747–758.
   PubMed Web of Science ®Google Scholar
• Ebenezer GJ, Hauer P, Gibbons C, et al. Assessment of epidermal nerve fibers: a new diagnostic and predictive tool for peripheral neuropathies. J Neuropathol Exp Neurol. 2007;66(12):1059–1073.
   PubMed Web of Science ®Google Scholar
• Hoitsma E, Faber CG, van Santen-Hoeufft M, et al. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23(1):73–77.
   PubMed Web of Science ®Google Scholar
• Tavee JO, Karwa K, Ahmed Z, et al. small fiber neuropathy in a large cohort: clinical aspects and response to IVIG and anti-TNF alpha treatment. Respir Med. 2017;126:135–138.
   PubMed Web of Science ®Google Scholar
• Culver DA, Dahan A, Bajorunas D, et al. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis- Associated small nerve fiber loss and neuropathic pain. Invest Ophthalmol Vis Sci. 2017;58(6):BIO52–BIO60.
   PubMed Web of Science ®Google Scholar
• Heij L, Niesters M, Swartjes M, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med. 2012;18:1430–1436.
   PubMed Web of Science ®Google Scholar
• Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J. 2012;40(1):255–263.
   PubMed Web of Science ®Google Scholar
• Chang B, Steimel J, Moller DR, et al. Depression in sarcoidosis. Am J Respir Crit Care Med. 2001;163(2):329–334.
   PubMed Web of Science ®Google Scholar
• Lal C, Medarov BI, Judson MA. Interrelationship between sleep-disordered breathing and sarcoidosis. Chest. 2015;148(4):1105–1114.
   PubMed Web of Science ®Google Scholar
• Lower EE, Malhotra A, Surdulescu V, et al. Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo- controlled, crossover trial. J Pain Symptom Manage. 2013;45(2):159–169.
   PubMed Web of Science ®Google Scholar
• Wagner MT, Marion SD, Judson MA. The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(3):235.
   PubMed Web of Science ®Google Scholar
• Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest. 2008;133(5):1189–1195.
   PubMed Web of Science ®Google Scholar
• Aggarwal AN, Sahu KK, Gupta D. Fatigue and health-related quality of life in patients with pulmonary sarcoidosis treated by oral Corticosteroids. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33(2):124–129.
   PubMed Web of Science ®Google Scholar
• Marcellis R, Van der Veeke M, Mesters I, et al. Does physical training reduce fatigue in sarcoidosis? Sarcoidosis Vasc Diffuse Lung Dis. 2015;32(1):53–62.
   PubMed Web of Science ®Google Scholar
• Verbraecken J, Hoitsma E, van der Grinten CP, et al. Sleep disturbances associated with periodic leg movements in chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21(2):137–146.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Sulaiman I, Rutherford R, et al. First presentation of sarcoidosis with severe obstructive sleep apnoea and epiglottic invilvement. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(2):146–148.
   PubMed Web of Science ®Google Scholar
• Pihtili A, Bingol Z, Kiyan E, et al. Obstructive sleep apnea is common in patients with interstitial lung disease. Sleep & Breathing = Schlaf & Atmung. 2013;17(4):1281–1288.
   PubMed Web of Science ®Google Scholar
• Series F, Cormier Y, Lampron N, et al. Increasing the functional residual capacity may reverse obstructive sleep apnea. Sleep. 1988;11(4):349–353.
   PubMed Web of Science ®Google Scholar
• Bingol Z, Pihtili A, Gulbaran Z, et al. Relationship between parenchymal involvement and obstructive sleep apnea in subjects with sarcoidosis. Clin Respir J. 2015;9(1):14–21.
   PubMed Web of Science ®Google Scholar
• James DG, Barter S, Jash D, et al. Sarcoidosis of the upper respiratory tract (SURT). J Laryngol Otol. 1982;96(8):711–718.
   PubMed Web of Science ®Google Scholar
• Moser NJ, Phillips BA, Guthrie G, et al. Effects of dexamethasone on sleep. Pharmacol Toxicol. 1996;79(2):100–102.
   PubMedGoogle Scholar
• Cox CE, Donohue JF, Brown CD, et al. Health-related quality of life of persons with sarcoidosis. Chest. 2004;125(3):997–1004.
   PubMed Web of Science ®Google Scholar
• Drent M, Wirnsberger RM, Breteler MH, et al. Quality of life and depressive symptoms in patients suffering from sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1998;15(1):59–66.
   PubMed Web of Science ®Google Scholar
• Drake WP, Dhason MS, Nadaf M, et al. Cellular recognition of Mycobacterium tuberculosis ESAT-6 and KatG peptides in systemic sarcoidosis. Infect Immune. 2007;75(1):527–530.
   PubMed Web of Science ®Google Scholar
• Drake WP, Oswald-Richter K, Richmond BW, et al. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. JAMA Dermatol. 2013;149(9):1040–1049.
   PubMed Web of Science ®Google Scholar
• Drake WP, Richmond BW, Oswald-Richter K, et al. Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(3):201–211.
   PubMed Web of Science ®Google Scholar
• Moller DR, Forman JD, Liu MC, et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol. 1996;156(12):4952–4960.
   PubMed Web of Science ®Google Scholar
• Homolka J, Müller-Quernheim J. Increased interleukin 6 production by bronchoalveolar lavage cells in patients with active sarcoidosis. Lung. 1993;171(3):173–183.
   PubMed Web of Science ®Google Scholar
• Takizawa H, Satoh M, Okazaki H, et al. Increased IL-6 and IL-8 in bronchoalveolar lavage fluids (BALF) from patients with sarcoidosis: correlation with the clinical parameters. Clin Exp Immunol. 1997;107(1):175–181.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Fleischmann R, Furst D, et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014;73(9):1607–1615.
   PubMed Web of Science ®Google Scholar
• Shigehara K, Shijubo N, Ohmichi M, et al. Increased levels of interleukin-18 in patients with pulmonary sarcoidosis. Am J Respir Crit Care Med. 2000;162(5):1979–1982.
   PubMed Web of Science ®Google Scholar
• Huho A, Foulke L, Jennings T, et al. The role of serum amyloid A staining of granulomatous tissues for the diagnosis of sarcoidosis. Respir Med. 2017;126:1–8.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Culver DA, Jankovi V, et al. Placenta-derived mesenchymal-like cells (PDA-001) as therapy for chronic pulmonary sarcoidosis: a phase 1 study. Sarcoidosis Vasc Diffuse Lung Dis. 2015;32(2):106–114.
   PubMed Web of Science ®Google Scholar
• Prasse A, Zissel G, Lützen N, et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med. 2010;182(4):540–548.
   PubMed Web of Science ®Google Scholar
• Rastogi R, Du W, Ju D, et al. Dysregulation of p38 and MKP-1 in response to NOD1/TLR4 stimulation in sarcoid bronchoalveolar cells. Am J Respir Crit Care Med. 2011;183:500–510.
   PubMed Web of Science ®Google Scholar
• Dotan I, Rachmilewitz D, Schreiber S, et al. Semapimod-CD04/CD05 Investigators. A randomised placebo-controlled multicenter trial of intravenous semapimod HCl for moderate to severe Crohn’s disease. Gut. 2010;59(6):760–766.
   PubMed Web of Science ®Google Scholar
• Buch MH, Vital EM, Emery P. Abatacept in the treatment of rheumatoid arthritis. Arthritis Res Ther. 2008;10(Suppl 1):S5.
   PubMedGoogle Scholar
• Chiarchiaro J, Chen BB, Gibson KF. New molecular targets for the treatment of sarcoidosis. Curr Opin Pulm Med. 2016;22(5):515–521.
   PubMed Web of Science ®Google Scholar
• Shao B-Z, Xu Z-Q, Han B-Z, et al. NLRP3 inflammasome and its inhibitors: a review. Front Pharmacol. 2015;6:262.
   PubMed Web of Science ®Google Scholar
• Drent M, van den Berg R, Haenen GR, et al. NF-kappaB activation in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18(1):50–56.
   PubMed Web of Science ®Google Scholar
• Julian MW, Shao G, Schlesinger LS, et al. Nicotine treatment improves Toll-like receptor 2 and Toll-like receptor 9 responsiveness in active pulmonary sarcoidosis. Chest. 2013;143(2):461–470.
   PubMed Web of Science ®Google Scholar
• Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6(12):1399–1402.
   PubMed Web of Science ®Google Scholar
• Chappell AG, Cheung WY, Hutchings HA. Sarcoidosis: a long-term follow up study. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17(2):167–173.
   PubMed Web of Science ®Google Scholar
• Moller DR. Pulmonary fibrosis of sarcoidosis. New approaches, old ideas. Am J Respir Cell Mol Biol. 2003;29(3 Suppl):S37–41.
   PubMed Web of Science ®Google Scholar
• Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(2):119–127.
   PubMed Web of Science ®Google Scholar
• Huang CT, Heurich AE, Sutton AL, et al. Mortality in sarcoidosis. A changing pattern of the causes of death. Eur J Respir Dis. 1981;62(4):231–238.
   PubMedGoogle Scholar
• Judson MA. Strategies for identifying pulmonary sarcoidosis patients at risk for severe or chronic disease. Expert Rev Respir Med. 2017;11(2):111–118.
   PubMed Web of Science ®Google Scholar
• Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082.
   PubMed Web of Science ®Google Scholar
• King TE Jr, Bradford WZ, Castro-Bernardini S, et al.; ASCEND Study Group; A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370(22):2083–2092.
   PubMed Web of Science ®Google Scholar
• Ligon CB, Judson MA. Impact of systemic corticosteroids on healthcare utilization in patients with sarcoidosis. Am J Med Sci. 2011;341(3):196–201.
   PubMed Web of Science ®Google Scholar
• Judson MA, Chaudhry H, Louis A, et al. The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis. Respir Med. 2015;109(4):526–531.
   PubMed Web of Science ®Google Scholar
• Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995;155(8):846–851.
   PubMedGoogle Scholar